Abemaciclib
- Generic Name
- Abemaciclib
- Brand Names
- Verzenio, Verzenios
- Drug Type
- Small Molecule
- Chemical Formula
- C27H32F2N8
- CAS Number
- 1231929-97-7
- Unique Ingredient Identifier
- 60UAB198HK
- Background
Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity. On September 28, 2017, FDA granted approval of abemaciclib treatment under the market name Verzenio for the treatment of HR-positive and HER2-negative a...
- Indication
适应症为:⑴单药治疗接受过内分泌疗法和化疗后疾病进展的 ER+/HER2-晚期或转移性乳腺癌；⑵或联合氟维司群，二线治疗接受过内分泌疗法后疾病进展的 ER+/HER2-晚期或转移性乳腺癌；⑶联合芳香酶抑制剂作为 ER+/HER2-绝经后女性晚期或转移性乳腺癌的初始内分泌疗法。
- Associated Conditions
- HR+, HER2-, Advanced Breast Cancer, Early Hormone Receptor Positive, HER2/Neu Negative Node Positive Breast Cancer, Metastatic HR + HER2 - breast cancer
- Associated Therapies
- -
Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer
- First Posted Date
- 2021-10-27
- Last Posted Date
- 2024-02-21
- Lead Sponsor
- Icahn School of Medicine at Mount Sinai
- Target Recruit Count
- 60
- Registration Number
- NCT05095207
- Locations
- 🇺🇸
Mount Sinai Beth Israel, New York, New York, United States
🇺🇸Mount Sinai - West, New York, New York, United States
🇺🇸Dubin breast Center, New York, New York, United States
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-07-23
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 866
- Registration Number
- NCT04975308
- Locations
- 🇺🇸
USO - Texas Oncology - Allen, Allen, Texas, United States
🇦🇺Ashford Cancer Centre Research, Kurralta Park, South Australia, Australia
🇺🇸Ironwood Cancer & Research Centers, Chandler, Arizona, United States
SARC041: Study of Abemaciclib Versus Placebo in Patients with Advanced Dedifferentiated Liposarcoma
- Conditions
- Interventions
- First Posted Date
- 2021-07-19
- Last Posted Date
- 2024-12-06
- Target Recruit Count
- 108
- Registration Number
- NCT04967521
- Locations
- 🇺🇸
Mayo Clinic Florida, Jacksonville, Florida, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
🇺🇸Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)
- Conditions
- Interventions
- First Posted Date
- 2021-07-16
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 300
- Registration Number
- NCT04964934
- Locations
- 🇬🇧
Research Site, Taunton, United Kingdom
A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)
- Conditions
- Interventions
- First Posted Date
- 2021-07-14
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 4200
- Registration Number
- NCT04961996
- Locations
- 🇺🇸
Centra Alan B. Pearson Regional Cancer Center, Lynchburg, Virginia, United States
🇬🇷University of Athens, Hematological Clinic,; First Department of Propaedeutic Medicine, Athens, Greece
🇺🇸Southern Cancer Center, Daphne, Alabama, United States
Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma
- First Posted Date
- 2021-06-28
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 86
- Registration Number
- NCT04941274
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors
- Conditions
- Interventions
- First Posted Date
- 2021-06-18
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 176
- Registration Number
- NCT04931342
- Locations
- 🇫🇷
CHU Besançon - Hôpital Jean Minjoz, Besançon Cedex, France
🇫🇷Institut Bergonie; Oncologie, Bordeaux, France
🇫🇷Centre Francois Baclesse; Oncologie, Caen, France
Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases
- Conditions
- Interventions
- First Posted Date
- 2021-06-11
- Last Posted Date
- 2024-11-28
- Target Recruit Count
- 31
- Registration Number
- NCT04923542
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
Abemaciclib Plus Ramucirumab for Esophageal/Gastroesophageal Junction Ca
- First Posted Date
- 2021-06-10
- Last Posted Date
- 2021-06-10
- Lead Sponsor
- Baylor Research Institute
- Target Recruit Count
- 30
- Registration Number
- NCT04921904
- Locations
- 🇺🇸
Baylor University Medical Center, Charles A Sammons Cancer Center, Dallas, Texas, United States
Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
- Conditions
- Interventions
- First Posted Date
- 2021-04-28
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 895
- Registration Number
- NCT04862663
- Locations
- 🇻🇳
Research Site, Vinh, Vietnam
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.